Erasca Shares Plunge After Patient Death Linked to Experimental Therapy
Erasca Inc. saw its stock slide sharply after the company revealed that a 66-year-old trial participant experienced severe lung inflammation about a month into treatment, withdrew from the study, and later died after discontinuing the experimental therapy. The disclosure accompanied early-stage trial data that the company described as generally wel…